InsiderSignal.AI

InsiderSignal.ai

ANIP - Ani Pharmaceuticals Inc

Insider Sale by Mutz Christopher (HEAD OF RARE DISEASE)

1 Month
After Trade
Before Trade

Loading data...

Trade Summary

2 days ago, Mutz Christopher, serving as HEAD OF RARE DISEASE at Ani Pharmaceuticals Inc (ANIP), sold 3,162 shares at $71.64 per share, for a total transaction value of $226,526.00. Following this transaction, Mutz Christopher now holds 91,309 shares of ANIP.

This sale represents a 3.00% decrease in Mutz Christopher's stake in the company. This is considered a medium-conviction trade.

The trade was executed on Friday, March 13, 2026 and publicly disclosed via SEC Form 4 filing on Friday, March 13, 2026, meaning the disclosure happened on the same day as the trade.

Ani Pharmaceuticals Inc operates in the HEALTHCARE sector, specifically within the DRUG MANUFACTURERS - SPECIALTY & GENERIC industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.

Mutz Christopher

HEAD OF RARE DISEASE

Christopher K. Mutz is a pharmaceutical executive serving as Senior Vice President and Head of Rare Disease at ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) since February 2021.[[2]](https://fintool.com/app/research/companies/ANIP/people/christopher-mutz) In this role, he has driven significant growth in the Rare Disease segment, with revenues increasing from $112.1 million in 2023 to $229.6 million in 2024, contributing to the company's total net revenues of $614.4 million and Adjusted non-GAAP EBITDA of $156.0 million, resulting in a 200% corporate bonus payout.[[2]](https://fintool.com/app/research/companies/ANIP/people/christopher-mutz) Mutz brings over 25 years of experience in the pharmaceutical industry, including leadership roles at Alexion Pharmaceuticals (2011–2019), where he led U.S. commercial operations and strategy for launches like SOLIRIS in rare diseases, and at Merck & Co. (2001–2011), managing oncology marketing in China and U.S. marketing for TEMODAR.[[2]](https://fintool.com/app/research/companies/ANIP/people/christopher-mutz) He holds a B.A. in Biology from the University of Virginia and an M.B.A. from Cornell University.[[2]](https://fintool.com/app/research/companies/ANIP/people/christopher-mutz) As of early 2026, Mutz owns approximately 103,508 to 107,317 shares of ANIP stock following recent transactions, including sales under a Rule 10b5-1 plan and restricted stock awards.[[1]](https://www.marketbeat.com/instant-alerts/christopher-mutz-sells-417-shares-of-ani-pharmaceuticals-nasdaqanip-stock-2026-03-04/)[[3]](https://www.investing.com/news/insider-trading-news/ani-pharmaceuticals-head-of-rare-disease-sells-30k-in-stock-93CH-4542641)[[5]](https://www.stocktitan.net/sec-filings/ANIP/form-4-ani-pharmaceuticals-inc-insider-trading-activity-56f4e8908056.html)[[6]](https://stockcircle.com/insider-trades/person/mutz-christopher)

View full insider profile →

Trade Price

$71.64

Quantity

3,162

Total Value

$226,526.00

Shares Owned

91,309

Trade Date

Friday, March 13, 2026

2 days ago

SEC Filing Date

Friday, March 13, 2026

HEALTHCAREDRUG MANUFACTURERS - SPECIALTY & GENERIC

About Ani Pharmaceuticals Inc

Company Overview

No company information available
View news mentioning ANIP

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/4753854

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime